Argenx says Vyvgart sales rose 54% in third quarter
Argenx says Vyvgart sales rose 54% in third quarter Oct 22 (Reuters) - Belgian-Dutch pharmaceutical firm argenx ARGX.BR said on Thursday that global sales of its leading autoimmune drug Vyvgart rose 54% in the third quarter, as it reached more patients.
Sales of Vyvgart, a prescription drug used to treat adults with generalized myasthenia gravis, an autoimmune disease that causes muscle weakness, were $1.7 billion in the third quarter, up from $1.13 billion a year ago.
Operating profit was $486 million, below analysts' average estimate of $565.82 million, according to I/B/E/S data
Argenx completed its $2.2 billion acquisition of Forte Biosciences in August, adding an experimental drug that has shown early promise in vitiligo and celiac disease to its portfolio
Its quarterly operating margin declined to 28.2% due to acquisition-related costs
Combined research and development, selling, general and administrative costs are now expected to be around $4 billion in 2026, including those related to the Forte deal
(Reporting by Lucie Barbier in Gdansk, editing by Milla Nissi-Prussak)
((Email: lucie.barbier@thomsonreuters.com))